This internationally unmatched test system for the pharma/biotech industry and medical market uses known mouse and human embryonic stem (ES) cell lines to develop innovative methods for the targeted preparation of differentiated cardiac muscle cells. The project is currently a fully developed concept in the R&D phase.

Investment capital will be used for:
1) Personnel costs: €544,000
2) Other direct costs: €1,018,000
3) Equipment: €252,000